Finding the Unknown: Exploring the Impact of Extended-Release Injectable Naltrexone Administration and Sedation Requirements on ICU Patients

Authors

Ammar Vohra
Alejandro Hallo
Mohmed Imran Gora
Chee Yao Lim, Corewell Health Fellow
Manmeet K. Gujral
Vidya P. Menon

Document Type

Article

Publication Date

9-2024

Publication Title

Chest Journal

Abstract

Alcohol Use Disorder (AUD) affects approximately 30 million patients in the United States, significantly straining healthcare with high morbidity and mortality. To combat this ongoing problem, various pharmacological agents, including extended-release injectable (ERI) naltrexone, have been introduced. ERI naltrexone could potentially influence sedation and analgesia in patients on invasive mechanical ventilation (IMV) due to opioid receptor antagonism. There is limited data on this effect. We aim to understand the impact of ERI naltrexone on ICU patients on IMV.

Volume

166

Issue

4 Supplement

First Page

A2401

Last Page

A2402

Recommended Citation

Vohra A, Hallo A, Gora MI, Lim CY, Gujral MK, Menon VP. Finding the unknown: exploring the impact of extended-release injectable naltrexone administration and sedation requirements on icu patients. Chest. 2024 Sept;166(4 Suppl):A2401-A2402. doi: 10.1016/j.chest.2024.06.1470

DOI

10.1016/j.chest.2024.06.1470